AARP’s analysis also found that seven of the 10 drugs are set to cost less than $100 per month – up from only two drugs in 2025 – once new policies to lower drug prices take effect. While three drugs – Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s cancer drug Imbruvica and Johnson & Johnson’s psoriasis drug Stelara – will still have comparatively higher price tags, Medicare Part D beneficiaries will benefit from a new out-of-pocket spending cap of $2,100 in 2026. Additionally, all stand-alone Part D plans included in the study will cover each drug in 2026, representing an increase from current coverage levels.
As highlighted in the analysis, the Centers for Medicare and Medicaid Services (CMS) noted these policies “could save enrollees a collective $1.5 billion in out-of-pocket expenses in 2026.”
While these findings represent positive progress toward lowering prescription drug prices for Americans struggling to afford their medications, lawmakers must continue to work in a bipartisan fashion to advance market-based solutions that hold Big Pharma accountable.
Read the full Report from AARP HERE.
Read more about Big Pharma’s egregious pricing practices and direct-to-consumer advertising on these 10 drugs HERE.
Read more on bipartisan, market-based solutions to hold Big Pharma accountable HERE.
